Thursday, 4 June 2015

Results of the CheckMate 057 study reported at ASCO 2015 annual meeting

Nivolumab is the first PD-1 inhibitor to statistically significantly improve overall survival (OS) vs docetaxel in previously treated patients with advanced non-squamous cell non-small cell lung cancer (NSCLC). It significantly improved overall response rate (ORR) as well. Safety profile of nivolumab was favourable in comparison to docetaxel and consistent with prior studies. CheckMate 057 is the second randomised phase III trial to demonstrate superior survival over docetaxel in patients with advanced NSCLC. Read more here

No comments:

Post a Comment